MX2009010660A - Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas. - Google Patents
Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas.Info
- Publication number
- MX2009010660A MX2009010660A MX2009010660A MX2009010660A MX2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- haloalkyl
- purine derivatives
- compounds
- independently
- Prior art date
Links
- -1 9-substituted purine Chemical class 0.000 title abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92189707P | 2007-04-04 | 2007-04-04 | |
| GBGB0706632.7A GB0706632D0 (en) | 2007-04-04 | 2007-04-04 | New purine derivatives |
| PCT/GB2008/001173 WO2008122767A2 (en) | 2007-04-04 | 2008-04-02 | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010660A true MX2009010660A (es) | 2010-02-17 |
Family
ID=38090893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010660A MX2009010660A (es) | 2007-04-04 | 2008-04-02 | Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8592581B2 (enExample) |
| EP (1) | EP2139893B1 (enExample) |
| JP (1) | JP5466145B2 (enExample) |
| CN (1) | CN101679434B (enExample) |
| AU (1) | AU2008235361B2 (enExample) |
| BR (1) | BRPI0809996B8 (enExample) |
| CA (1) | CA2681529C (enExample) |
| ES (1) | ES2427845T3 (enExample) |
| GB (1) | GB0706632D0 (enExample) |
| MX (1) | MX2009010660A (enExample) |
| PL (1) | PL2139893T3 (enExample) |
| RU (1) | RU2461559C2 (enExample) |
| WO (1) | WO2008122767A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0903346D0 (en) | 2009-02-27 | 2009-04-08 | Cambridge Advanced Tech | Transgenic Plants |
| GB201001075D0 (en) * | 2010-01-22 | 2010-03-10 | Cyclacel Ltd | Crystalline forms |
| DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
| PL3244891T3 (pl) | 2015-01-16 | 2022-12-27 | The General Hospital Corporation | Związki poprawiające splicing mRNA |
| JP6591036B2 (ja) | 2016-02-26 | 2019-10-16 | 公益財団法人がん研究会 | Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
| AU2018213119B2 (en) * | 2017-01-26 | 2021-10-28 | Cyclacel Limited | Process for preparing purine derivatives |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| US12240869B2 (en) | 2018-11-01 | 2025-03-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
| GB202000901D0 (en) | 2020-01-22 | 2020-03-04 | Cyclacel Ltd | Process |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
| KR20250121114A (ko) | 2022-12-16 | 2025-08-11 | 아스트라제네카 아베 | 2,6,9-삼치환된 퓨린 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| DE60023268T2 (de) * | 1999-02-01 | 2006-06-01 | CV Therapeutics, Inc., Palo Alto | INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha |
| US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| WO2003002565A1 (en) * | 2001-06-27 | 2003-01-09 | Cyclacel Limited | 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| US6812232B2 (en) * | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| MXPA05007503A (es) * | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| PL1799230T3 (pl) * | 2004-08-27 | 2013-05-31 | Cyclacel Ltd | Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych |
| GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
-
2007
- 2007-04-04 GB GBGB0706632.7A patent/GB0706632D0/en not_active Ceased
-
2008
- 2008-04-02 JP JP2010501585A patent/JP5466145B2/ja not_active Expired - Fee Related
- 2008-04-02 PL PL08718980T patent/PL2139893T3/pl unknown
- 2008-04-02 WO PCT/GB2008/001173 patent/WO2008122767A2/en not_active Ceased
- 2008-04-02 MX MX2009010660A patent/MX2009010660A/es active IP Right Grant
- 2008-04-02 CA CA2681529A patent/CA2681529C/en active Active
- 2008-04-02 EP EP08718980.9A patent/EP2139893B1/en active Active
- 2008-04-02 ES ES08718980T patent/ES2427845T3/es active Active
- 2008-04-02 RU RU2009140753/04A patent/RU2461559C2/ru active
- 2008-04-02 AU AU2008235361A patent/AU2008235361B2/en not_active Ceased
- 2008-04-02 CN CN2008800189406A patent/CN101679434B/zh not_active Expired - Fee Related
- 2008-04-02 BR BRPI0809996A patent/BRPI0809996B8/pt not_active IP Right Cessation
-
2009
- 2009-10-05 US US12/573,337 patent/US8592581B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5466145B2 (ja) | 2014-04-09 |
| CN101679434A (zh) | 2010-03-24 |
| CA2681529C (en) | 2015-06-30 |
| CA2681529A1 (en) | 2008-10-16 |
| JP2010523534A (ja) | 2010-07-15 |
| BRPI0809996B1 (pt) | 2019-09-03 |
| EP2139893A2 (en) | 2010-01-06 |
| WO2008122767A3 (en) | 2008-12-31 |
| EP2139893B1 (en) | 2013-06-19 |
| US8592581B2 (en) | 2013-11-26 |
| PL2139893T3 (pl) | 2013-11-29 |
| BRPI0809996A2 (pt) | 2014-10-14 |
| GB0706632D0 (en) | 2007-05-16 |
| ES2427845T3 (es) | 2013-11-04 |
| BRPI0809996B8 (pt) | 2021-05-25 |
| RU2461559C2 (ru) | 2012-09-20 |
| US20100093769A1 (en) | 2010-04-15 |
| RU2009140753A (ru) | 2011-05-10 |
| WO2008122767A2 (en) | 2008-10-16 |
| AU2008235361A1 (en) | 2008-10-16 |
| AU2008235361B2 (en) | 2013-02-14 |
| CN101679434B (zh) | 2013-09-25 |
| HK1139939A1 (en) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008122767A3 (en) | 2, 6, 9-substituted purine derivatives having anti proliferative properties | |
| AR065276A1 (es) | Herbicidas de n-oxidos de piridina sustituidos | |
| NO20085385L (no) | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav | |
| TW200740773A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
| NO20060324L (no) | [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni | |
| MY161903A (en) | Substituted piperidines as ccr3 antagonists | |
| NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
| ATE523514T1 (de) | Tricyclische triazolische verbindungen | |
| PT1902037E (pt) | 2,4-diamino-pirimidinas como inibidores de aurora | |
| NO20090760L (no) | Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet | |
| ES2531324T3 (es) | Intermedio para producir un derivado de gamma-aminoácido bicíclico | |
| MX2009005185A (es) | Analogos de tiofeno para el tratamiento o prevencion de infecciones de flavivirus. | |
| JO2910B1 (en) | Organic compounds | |
| TW200716121A (en) | Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
| TW200628154A (en) | Organic compounds | |
| MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
| NO20092689L (no) | Quinuclidinolderivater som muskarin reseptorantagonister | |
| BR112012007411A2 (pt) | composto, processo para sua preparação e composição farmacêutica contendo o mesmo | |
| NO20055688L (no) | Organiske forbindelser | |
| TW200745056A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
| ATE354574T1 (de) | Neue purine derivate | |
| MX2010004876A (es) | Derivados de diamido tiazol como inhibidores de la proteina cinasa. | |
| IL205045A (en) | Piperidinyl and piperazine derivatives, preparations containing them and their uses | |
| BRPI0519292A2 (pt) | compostos orgÂnicos | |
| UY30673A1 (es) | Derivados 6, 7 y 8 sustituidos del acido (3r)-5-oxo-2,3-dihidro-5h-tiazolo[3,2a]piridin-3-carboxilico, composiciones farmacéuticas conteniéndolos y aplicaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |